Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus

References

• Tell LA. Aspergillosis in mammals and birds: impact on veterinary medicine. Med Mycol 2005; 43 (Suppl. 1): S71–73.
   Google Scholar
• Orosz SE. Antifungal drug therapy in avian species. Vet Clin North Am Exot Anim Pract 2003;6:337–350.
   PubMedGoogle Scholar
• Orosz SE, Frazier DL. Antifungal agents: a review of their pharmacology and therapeutic indications. J Avian Med Surg 1995;9:8–18.
   Google Scholar
• Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310–344.
   PubMed Web of Science ®Google Scholar
• Denning DW, Lee JY, Hostetler JS, . NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135–144.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, . Guidelines for the treatment of aspergillosis (Infectious Diseases Society of America practice guidelines). Clin Infect Dis 2008;46:327–360.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Ruhnke M, Ribaud P, . Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106:2641–2645.
   PubMed Web of Science ®Google Scholar
• Mouas H, Lutsar I, Dupont B, . Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005;40:1141–1147.
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630–637.
   PubMed Web of Science ®Google Scholar
• Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother 2005;6:1215–1229.
   PubMed Web of Science ®Google Scholar
• Capitano B, Potoski BA, Husain S, . Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006;50:1878–1880.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Manavathu EK, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005;55:914–920.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005;49:4867–4875.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Parmar R, Martinez M, Stevens DA. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 2006;58:466–469.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006;44:69–73.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000;44:2865–2868.
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:3165–3169.
   PubMed Web of Science ®Google Scholar
• Roffey SJ, Cole S, Comby P, . The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003;31:731–741.
   PubMed Web of Science ®Google Scholar
• Colitz CM, Latimer FG, Cheng H, . Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses. Am J Vet Res 2007;68:1115–1121.
   PubMedGoogle Scholar
• Davis JL, Salmon JH, Papich MG. Pharmacokinetics of voriconazole after oral and intravenous administration to horses. Am J Vet Res 2006;67:1070–1075.
   PubMedGoogle Scholar
• Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Am J Vet Res 2006;67:296–301.
   PubMed Web of Science ®Google Scholar
• Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274–284.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649–663.
   PubMed Web of Science ®Google Scholar
• Flammer K, Nettifee Osborne JA, Webb DJ, . Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh). Am J Vet Res 2008;69:114–121.
   PubMedGoogle Scholar
• Beernaert LA, Baert K, Marin P, . Designing voriconazole treatment for racing pigeons: balancing between hepatic enzyme auto induction and toxicity. Med Mycol 2008;46:1–10.
   PubMedGoogle Scholar
• Burhenne J, Haefeli WE, Hess M, Scope A. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens. J Avian Med Surg 2008;22:199–207.
   PubMed Web of Science ®Google Scholar
• Schmidt V, Demiraj F, Di Somma A, . Plasma concentrations of voriconazole in falcons. Vet Rec 2007;161:265–268.
   PubMed Web of Science ®Google Scholar
• Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004;38:1907–1915.
   PubMed Web of Science ®Google Scholar
• Stevens DA, Aristizabal BH. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole. Diagn Microbiol Infect Dis 1997;29:103–106.
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa. 1998.
   Google Scholar
• Hanson LH, Clemons KV, Denning DW, Stevens DA. Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol 1995;33:311–317.
   PubMedGoogle Scholar
• Denning DW, Clemons KV, Stevens DA. Quantitative preservation of viability of Aspergillus fumigatus. J Med Vet Mycol 1992;30:485–488.
   PubMedGoogle Scholar
• Clemons KV, Stevens DA. Conventional or molecular measurement of Aspergillus load. Med Mycol 2008; 47 (Suppl. 1): S132–S137.
   Google Scholar
• Singh G, Imai J, Clemons KV, Stevens DA. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother. 2005;49:1369–1376.
   PubMed Web of Science ®Google Scholar
• Rex JH, Hanson LH, Amantea MA, Stevens DA, Bennett JE. Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother 1991;35:846–850.
   PubMed Web of Science ®Google Scholar
• Hoeprich PD, Finn PD. Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis 1972;126:353–361.
   PubMed Web of Science ®Google Scholar
• Silvanose CD, Bailey TA, Di Somma A. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole. Vet Rec 2006;159:282–284.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.
   PubMed Web of Science ®Google Scholar
• Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002; 3: 4
   PubMedGoogle Scholar
• Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials 1999;20:408–422.
   PubMedGoogle Scholar
• Purkins L, Wood N, Ghahramani P, . Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546–2553.
   PubMed Web of Science ®Google Scholar
• Patterson B, Coates P. UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: disposition in man . Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995; Abstract F76.
   Google Scholar
• Sugar AM, Liu XP. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000;38:209–212.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Gonzalez GM, Hernandez S, Bocanegra R. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 2003;51:1373–1376.
   PubMed Web of Science ®Google Scholar
• Di Somma A, Bailey T, Silvanose CD, Garcia-Martinez C. The use of voriconazole for the treatment of aspergillosis in falcons (Falco Species). J Avian Med Surg 2007;21:307–316.
   PubMed Web of Science ®Google Scholar
• Serena C, Pastor FJ, Marine M, Rodriguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007;60:162–165.
   PubMed Web of Science ®Google Scholar
• Carrasco L, Bautista MJ, de las Mulas JM, Jensen HE. Application of enzyme-immunohistochemistry for the diagnosis of aspergillosis, candidiasis, and zygomycosis in three lovebirds. Avian Dis 1993;37:923–927.
   PubMed Web of Science ®Google Scholar
• Jensen HE, Christensen JP, Bisgaard M, Nielsen OL. Immunohistochemistry for the diagnosis of aspergillosis in turkey poults. Avian Path 1997; 26: 5–18
   PubMed Web of Science ®Google Scholar